Collegium Pharmaceutical (COLL) Current Assets (2014 - 2026)

Collegium Pharmaceutical's Current Assets history runs 13 years deep, the most recent figure standing at $745.7 million for Q1 2026.

• On a quarterly basis, Current Assets rose 41.34% year-over-year to $745.7 million in Q1 2026; TTM through Mar 2026 was $745.7 million, a 41.34% increase from a year earlier, with the FY2025 full-year figure at $691.4 million, up 43.37% from the prior year.
• Current Assets improved to $745.7 million in Q1 2026 per COLL's latest filing, from $691.4 million in the prior quarter.
• Across five years, Current Assets topped out at $745.7 million in Q1 2026 and bottomed at $363.6 million in Q1 2022.
• The 5-year median for Current Assets is $527.6 million (2025), against an average of $518.4 million.
• Across the five-year window, Current Assets slipped 17.37% in 2024 and soared 43.37% in 2025, its largest moves.
• Year by year, Current Assets stood at $420.0 million in 2022, then grew by 28.0% to $537.6 million in 2023, then dropped by 10.29% to $482.3 million in 2024, then jumped by 43.37% to $691.4 million in 2025, then grew by 7.85% to $745.7 million in 2026.
• Per Business Quant, the three latest COLL Current Assets figures stand at $745.7 million (Q1 2026), $691.4 million (Q4 2025), and $613.9 million (Q3 2025).